PA8562201A1 - Formulaciones de acitromicina directamente compresibles - Google Patents

Formulaciones de acitromicina directamente compresibles

Info

Publication number
PA8562201A1
PA8562201A1 PA20028562201A PA8562201A PA8562201A1 PA 8562201 A1 PA8562201 A1 PA 8562201A1 PA 20028562201 A PA20028562201 A PA 20028562201A PA 8562201 A PA8562201 A PA 8562201A PA 8562201 A1 PA8562201 A1 PA 8562201A1
Authority
PA
Panama
Prior art keywords
acithromycin
tablet
formulations
pharmaceutically acceptable
acceptable excipient
Prior art date
Application number
PA20028562201A
Other languages
English (en)
Inventor
Barbara Alice Johnson
Brendan John Murphy
Steven William Collier
Ernest Shing Quan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8562201A1 publication Critical patent/PA8562201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA MEZCLA EN SECO, UTILIZADA PARA FORMAR COMPRIMIDOS DE ACITROMICINA POR COMPRESION DIRECTA, QUE COMPRENDE ACITROMICINA NO DIHIDRATADA Y AL MENOS UN EXCIPIENTE FARMACEUTICAMENTE ACEPTABLE. ESTA INVENCION SE REFIERE TAMBIEN A UN COMPRIMIDO DE ACITROMICINA QUE COMPRENDE ACITROMICINA NO DIHIDRATADA Y AL MENOS UN EXCIPIENTE FARMACEUTICAMENTE ACEPTABLE. PREFERIBLEMENTE, EL COMPRIMIDO DE ACITROMICINA SE FORMA MEDIANTE COMPRESION DIRECTA DE LA MEZCLA EN SECO, DE LA PRESENTE INVENCION, PARA FORMAR DICHO COMPRIMIDO DE ACITROMICINA. PREFERIBLEMENTE, EL COMPRIMIDO DE ACITROMICINA, DE LA PRESENTE INVENCION, CONTIENE UNA DOSIFICACION DE 250 MGA, 500 MGA O 600MGA DE ACITROMICINA. ESTA INVENCION SE REFIERE ADEMAS A UN COMPRIMIDO DE ACITROMICINA QUE SE PRODUCE FORMANDO UNA MEZCLA EN SECO DE UNA FORMA A DE ACITROMICINA NO GRANULADA, Y AL MENOS UN EXCIPIENTE FARMACEUTICAMENTE ACEPTABLE. EL COMPRIMIDO DE ACITROMICINA SE FORMA A CONTINUACION MEDIANTE COMPRESION DIRECTA DE LA MEZCLA EN SECO.
PA20028562201A 2001-12-21 2002-12-20 Formulaciones de acitromicina directamente compresibles PA8562201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34348001P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
PA8562201A1 true PA8562201A1 (es) 2003-07-28

Family

ID=23346277

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20028562201A PA8562201A1 (es) 2001-12-21 2002-12-20 Formulaciones de acitromicina directamente compresibles

Country Status (20)

Country Link
US (4) US20030165563A1 (es)
EP (1) EP1455758A1 (es)
JP (1) JP2005513099A (es)
KR (1) KR100632339B1 (es)
CN (1) CN1668282A (es)
AR (1) AR037930A1 (es)
AU (1) AU2002348884A1 (es)
BR (1) BR0215193A (es)
CA (1) CA2469246A1 (es)
IL (1) IL161996A0 (es)
MX (1) MXPA04005105A (es)
NO (1) NO20043110L (es)
NZ (1) NZ532707A (es)
PA (1) PA8562201A1 (es)
PE (1) PE20030591A1 (es)
PL (1) PL371259A1 (es)
RU (1) RU2277914C2 (es)
TW (1) TW200301138A (es)
WO (1) WO2003053416A1 (es)
ZA (1) ZA200403486B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
JP2005513099A (ja) * 2001-12-21 2005-05-12 ファイザー・プロダクツ・インク アジスロマイシンの直接的に圧縮可能な配合品
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
GB0211620D0 (en) * 2002-05-21 2002-07-03 Bioprogress Technology Ltd Powder compaction and enrobing
US20030228370A1 (en) * 2002-06-11 2003-12-11 Michel Serpelloni Orodispersible solid pharmaceutical form
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
US20070185194A1 (en) * 2003-07-01 2007-08-09 Kamal Mehta Stable oral compositions of azithromycin monohydrate
WO2005004919A2 (en) * 2003-07-02 2005-01-20 Eurand, Inc. Extended release systems for macrolide antibiotics
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
ATE399536T1 (de) 2003-12-04 2008-07-15 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
BRPI0417348A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
CA2547597A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
CA2547239A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
WO2006067577A2 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Stable non-dihydrate azithromycin oral suspensions
US7901710B2 (en) * 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
US20100179110A1 (en) * 2006-12-20 2010-07-15 Mostafa Akbarieh Composition Containing a Bisphosphonic Acid in Combination with Vitamin D
US20100273873A1 (en) * 2007-07-31 2010-10-28 Katleen Rosa Francois Brys Direct compressible dextrose
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
WO2009116887A1 (ru) * 2008-03-18 2009-09-24 Dikovskiy Aleksander Vladimiro Фармацевтическая композиция антибиотиков и пребиотиков для профилактики и лечения дисбиозов в процессе антибактериальной терапии
WO2009116886A1 (ru) * 2008-03-18 2009-09-24 Dikovskiy Aleksander Vladimiro Фармацевтическая композиция и способ профилактики дисбиозов, ассоциированных с энтеральным приемом антибиотиков
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
KR20150092385A (ko) 2014-02-03 2015-08-13 씨제이헬스케어 주식회사 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법
US20150242974A1 (en) 2014-02-24 2015-08-27 Mindojo Ltd. Adaptive e-learning engine with embedded datagraph structure
US20160145548A1 (en) * 2014-11-20 2016-05-26 The Procter & Gamble Company Cleaning composition refill for an automatic dishwasher dispensing device
CN105193753A (zh) * 2015-10-30 2015-12-30 成都通德药业有限公司 一种阿奇霉素分散片的制备方法
CN110633487B (zh) * 2019-07-03 2023-03-14 北京中医药大学 直接压片的片剂处方的设计方法
CN111467362B (zh) * 2020-05-09 2021-07-06 北京四环制药有限公司 一种阿奇霉素药用组合物及其制备方法和其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
UA27040C2 (uk) 1987-07-09 2000-02-28 Пфайзер Інк. Кристалічhий дигідрат азитроміциhу та спосіб одержаhhя кристалічhого дигідрату азитроміциhу
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
TW271400B (es) * 1992-07-30 1996-03-01 Pfizer
US5795871A (en) * 1994-04-26 1998-08-18 Nobuhiro Narita Pharmaceutical composition for treatment of non-small cell lung cancer
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
CN1096862C (zh) * 1994-05-06 2002-12-25 辉瑞大药厂 阿齐霉素的控释剂型
IL119866A (en) 1996-12-19 1999-12-31 Unipharm Ltd Antibiotic tablet
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US6339063B1 (en) * 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
WO1999012552A1 (en) * 1997-09-10 1999-03-18 Merck & Co., Inc. 9a-AZALIDES AS VETERINARY ANTIMICROBIAL AGENTS
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
CZ20011886A3 (cs) * 1998-11-30 2001-10-17 Teva Pharmaceutical Industries Ltd. Etanolát azitromycinu, postup přípravy a jeho farmaceutické preparáty
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
ES2177373B1 (es) 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
AU2001214115A1 (en) 2000-08-01 2002-02-13 Habil F. Khorakiwala Process for the preparation of anhydrous azithromycin
EE200300575A (et) * 2001-05-22 2004-04-15 Pfizer Products Inc. Asitromütsiini kristalsed vormid
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
HUP0402291A2 (hu) * 2001-10-18 2005-03-29 Teva Pharmaceutical Industries Ltd. Stabilizált azithromycin összetételek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
RU2283651C2 (ru) * 2001-12-21 2006-09-20 Пфайзер Продактс Инк. Способы мокрой грануляции азитромицина
JP2005513099A (ja) * 2001-12-21 2005-05-12 ファイザー・プロダクツ・インク アジスロマイシンの直接的に圧縮可能な配合品
EP1478347A1 (en) * 2002-02-01 2004-11-24 Pfizer Products Inc. Dry granulated formulations of azithromycin

Also Published As

Publication number Publication date
EP1455758A1 (en) 2004-09-15
NO20043110L (no) 2004-07-20
ZA200403486B (en) 2006-05-31
AR037930A1 (es) 2004-12-22
JP2005513099A (ja) 2005-05-12
KR20040066175A (ko) 2004-07-23
US20060024363A1 (en) 2006-02-02
RU2277914C2 (ru) 2006-06-20
IL161996A0 (en) 2005-11-20
US7070811B2 (en) 2006-07-04
US20030165563A1 (en) 2003-09-04
RU2004118709A (ru) 2005-04-20
WO2003053416A1 (en) 2003-07-03
US20050287209A1 (en) 2005-12-29
TW200301138A (en) 2003-07-01
BR0215193A (pt) 2004-11-16
PL371259A1 (en) 2005-06-13
KR100632339B1 (ko) 2006-10-12
US20060024364A1 (en) 2006-02-02
MXPA04005105A (es) 2004-08-19
PE20030591A1 (es) 2003-07-12
AU2002348884A1 (en) 2003-07-09
CN1668282A (zh) 2005-09-14
CA2469246A1 (en) 2003-07-03
NZ532707A (en) 2006-07-28

Similar Documents

Publication Publication Date Title
PA8562201A1 (es) Formulaciones de acitromicina directamente compresibles
CO5390072A1 (es) Compuestos organicos
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
CY1118211T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν ενωσεις λανθανιου
ES2181417T3 (es) Formulacion de capsulas o tabletas de efavirenz de disolucion rapida usando super-desintegrantes.
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
WO2004000197A3 (en) Quick dissolve compositions and tablets based thereon
AR031682A1 (es) Composiciones farmaceuticas
AR049000A1 (es) Formulacion para compresion directa y proceso para la preparacion de una tableta directamente comprimida
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
SG146608A1 (en) Rapid dissolution formulation of a calcium receptor-active compound
MX9308188A (es) Glucomanano de konjac facilmente disponible, como un excipiente de liberacion sostenida.
AR030829A1 (es) Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal
CO5650230A2 (es) Composiciones estables de atorvastatina preparadas con granulacion en humedo
CO4940406A1 (es) Composiciones de paracetamol de accion rapida
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
BR0209644A (pt) Processo de compactação para fabricação de uma forma de dosagem de fenitoìna de sódio
AR036085A1 (es) Formas de dosificacion y procedimiento para su fabricacion
PE20010540A1 (es) Composicion de fitoalexinas estilbenicas util para la profilaxis y tratamiento de sintomas asociados con el resfriado y enfermedades similares a la influenza
DE60309472D1 (de) Pharmazeutische formulierung mit einem nichtpeptidischen renin-hemmer und surfactant
UY27599A1 (es) Formulaciones de acitromicina directamente compresibles
PA8592501A1 (es) Complejos de e-2-metoxi-n-(3-{4-[3-metil-4(6-metilpiridin-3-iloxi)fenilamino]quinazolin-6-il}alil)acetamida, su procedimiento de produccion y uso
CL2004001317A1 (es) Composicion farmaceutica que comprende el antagonista de receptores de progesterona 11b-(4-acetilfenil)-17b-hidroxi-17 alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno puro; y su uso para tratar una enfermedad dependiente de h
PL378106A1 (pl) Sposób wytwarzania zawierającej fibrat kompozycji farmaceutycznej w postaci tabletek oraz tabletki otrzymane tym sposobem